Alzheimer's disease is a complex condition that starts to develop decades before symptoms appear. Early signs include memory problems and difficulties with complex tasks. These signs can be subtle and people often think this is a result of ageing. In the early stages of Alzheimer's disease, certain regions in the brain crucial for memory are affected. This causes the frequency and severity of memory lapses to become more evident than with normal aging.
Our brains communicate through a vast network of billions of nerve cells. These nerve cells connect with each other through connections called 'synapses'. Throughout our lives we lose and regrow these brain connections. In a healthy brain the amount of new synapses generated balances the loss of older ones. In the case of Alzheimer's disease, the rate at which these connections are damaged accelerates so that new ones formed can no longer compensate for those lost. This is when the brain network starts to fail and symptoms such as memory loss appear.
Nutricia's pledge to providing the Best Care in the field of Alzheimer's disease
Meet the patients, carers and healthcare professionals who are benefitting from Nutricia’s approach to the dietary management of early Alzheimer’s Disease.
Nutrition and the brain
Nutrients within food are important for keeping the brain tissue healthy. Specific key nutrients are important to help build the brain connections or synapses.
These nutrients are :
- Omega 3 fatty acids
- B Vitamins
Studies have shown that people with early Alzheimer's disease often have low levels of these key nutrients, despite eating a normal diet. Increased intake of these nutrients is necessary because the pathways supporting synapse formation and function depend on them. Research has shown that taking these single nutrients alone or together has not consistently demonstrated benefits in early Alzheimer's disease. In contrast, a multi-nutrient combination, taken daily at the right levels, have shown benefits in clinical trials in early AD. Other benefits that have been reported by patients taking this multi-nutrient combination, are lower levels of apathy, increased energy, alertness and improved mood. This was reported to lead to increasing social interactions, renewed interest in hobbies and restarting activities recently stopped due to the illness.
Souvenaid is a new approach in medical nutrition for people with early Alzheimer's disease, that has been clinically proven to improve memory.
Souvenaid provides a unique combination of nutrients to support synapse formation for people in the early stages of Alzheimer's disease.
- Omega 3 fatty acids
- B Vitamins
Souvenaid is a convenient once-daily drink available in three flavours: vanilla, strawberry, cappuccino.
Pioneering nutritional discoveries
Souvenaid is the result of an extensive research programme spanning more than a decade. Discovered by top scientists at Massachusetts Institute of Technology (MIT), over 10 years of preclinical data has demonstrated that by providing the combination of key nutrients, markers for synapse formation can be increased.
Two randomised controlled trials, assessing almost 500 drug naïve patients demonstrated improved memory performance in people with mild Alzheimer's disease over 12 and 24 weeks respectively.¹⁻²
An additional 24 week open label extension showed further improvement in memory performance over 48 weeks including positive safety and adherence data.³ Observational data have reported that in addition to improvements in memory, there are noticeable benefits in levels of apathy, mood, engagement and activities of daily living.⁴⁻⁵
An EU funded randomised controlled trial is investigating Souvenaid in prodromal Alzheimer's disease subjects over 24 months.* The LipiDiDiet⁶ trial will explore the effect of Souvenaid on cognition, function, mood, biomarkers and disease progression.
¹ Scheltens P, et al. Alzheimers Dement. 2010;6:1-10.e1.
² Scheltens P, et al. J Alzheimer's Dis.2012;31:225-236.
³ Olde Rikkert MG, et al. J Alzheimers Dis. 2015;44(2):471-80.
⁴ Bianchetti A et al. Psicogeriatria 2014; 9(2):66-75.
⁵ Kalisvaart CJ et al. European Geriatric Medicine 2014; 5 (S1): 98. Poster P051.
⁶ Freund-Levi Y, et al. J Nutr Health Aging. 2012; 16(9): 859.
*LipiDiDiet, is registered under the European Union's 7th Framework Programme for research, technological development and demonstration (grant agreement number 211696).
At Nutricia we are proud to share news that the first results of the EU funded LipiDiDiet Trial were presented at AAT in Athens in March 2016. This is the first randomised control trial with a nutritional intervention to complete in prodromal Alzheimer's disease over a 2 year period.
For further information
Nutricia products are intended for the nutritional management of diseases and related medical conditions and therefore should be used under medical supervision.